Compounded transdermal pain management

Patent metadata

Field	Value
Publication number	US-9724315-B2
Application number	US-201113328369-A
Country	US
Kind code	B2
Filing date	Dec 16, 2011
Priority date	Sep 30, 2011
Publication date	Aug 8, 2017
Grant date	Aug 8, 2017

Abstract

The present embodiments relate to topically delivered medication (compounded) for treatment of pain, inflammation, muscle fatigue, spasms, and/or other ailments. A transdermal cream may provide the effective topical administration of multiple medications simultaneously. The transdermal cream may include a salt load of approximately 30% or greater. The transdermal cream may include a unique base composition such that the transdermal cream may be able to remain stable and avoid degradation for six months or more and capable of effective delivery of active ingredient concentrations exceeding approximately 40% or more of the total formulation weight. The active ingredients may include a nerve depressant, NSAID, muscle relaxant, opiate agonist, local anesthetic, NMDA receptor antagonist, and a tricyclic antidepressant. In one embodiment, the transdermal cream may comprise ketamine HCL, gabapentin, clonidine HCL and baclofen. The transdermal cream may deliver an enhanced topical delivery flux of ketamine via a single transdermal application.

First claim

What is claimed is:

1. A compounded transdermal pain management cream for topical administration of multiple medications simultaneously, the compounded transdermal pain management cream comprising:
several medications within a base composition for topical administration to a patient, the several medications including
at least one nerve depressant; at least one NSAID (Non-Steroidal Anti-Inflammatory Drug);
at least one muscle relaxant;
at least one opioid or opiate agonist;
at least one local anesthetic, wherein the at least one local anesthetic is in an amount between approximately 1.0% and approximately 5% of the transdermal cream by weight; and at least one NMDA (N-Methyl-D-aspartate) receptor antagonist comprising ketamine in an amount of 30% to 40% of the transdermal cream by weight, and
at least one tricyclic antidepressant,
wherein the several medications comprise approximately 40% or more of the transdermal cream by weight.

Assignees

• Ray Ii Jay Richard
• Hodge Charles D
• Cmpd Licensing Llc

Inventors

• Ray Ii Jay Richard
• Hodge Charles D

Classifications

• A61P29/00

  Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID] · CPC title

• A61P25/24

  Antidepressants · CPC title

• A61K31/4168

  having a nitrogen attached in position 2, e.g. clonidine · CPC title

• A61K31/167

  having the nitrogen of a carboxamide group directly attached to the aromatic ring, e.g. lidocaine, paracetamol · CPC title

• A61K31/135 Primary

  having aromatic rings {, e.g. ketamine, nortriptyline (methadone A61K31/137)} · CPC title